Alpha-Synuclein PMCA Fluorescence for PD-MSA Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Parkinson's disease (PD) and multiple system atrophy (MSA) are not specific and sensitive enough to distinguish between the two conditions, leading to misdiagnosis and inadequate treatment.
Innovation Solution
A method using protein misfolding cyclic amplification (PMCA) with a pre-incubation mixture containing a monomeric αS substrate, buffer, salt, and indicator, followed by multiple incubation cycles and fluorescence detection, to form and detect misfolded αS aggregates, allowing differentiation between PD and MSA based on fluorescence emission intensity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for PD and MSA, then diagnosis can be performed, but the specificity and sensitivity are insufficient leading to misdiagnosis
Solution Approach 1:
The method performs preliminary enrichment of misfolded alpha-synuclein aggregates from biological samples before detection. This preliminary action concentrates the target analyte, enabling subsequent highly specific detection methods to achieve both high measurement precision and diagnostic reliability by eliminating dilution effects and enhancing signal-to-noise ratios
Solution Approach 2:
The invention uses specific antibodies as intermediaries that selectively bind to misfolded alpha-synuclein aggregates. These antibody intermediaries enable highly specific detection by bridging the target pathogen (misfolded protein) and the detection system, thereby achieving both high precision measurement and reliable diagnosis
2Measurement precision
If soluble misfolded alpha-synuclein protein is detected directly in bodily fluids, then detection can be performed, but the low concentration makes detection very difficult
Solution Approach 1:
The method performs preliminary enrichment and concentration of misfolded alpha-synuclein from dilute biological samples before detection. This preliminary concentration step overcomes the low quantity problem by accumulating sufficient target material, thereby enabling sensitive detection despite the originally low protein concentration in bodily fluids
Solution Approach 2:
The invention changes the concentration parameter of misfolded alpha-synuclein by performing enrichment steps that increase analyte concentration from trace levels to detectable levels. This parameter transformation enables sensitive detection by converting the low-concentration sample into a high-concentration detectable form
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides high specificity and sensitivity in distinguishing between PD and MSA, enabling early and accurate diagnosis, guiding appropriate treatment and improving quality of life for MSA patients.
Implementation Method 1
detecting via indicator fluorescence emission the misfolded αS aggregates
Data Source
AI summary
A method is provided for distinguishing between and/or diagnosing Parkinson's disease (PD) or multiple system atrophy (MSA) in a subject who is exhibiting symptoms associated with both PD and MSA. The method comprises: (A) contacting a biological sample obtained from the subject and comprising soluble, misfolded alpha-synuclein (αS) protein with a pre-incubation mixture comprising a monomeric αS substrate and an indicator to form an incubation mixture; (B) conducting an incubation cycle two or more times on the incubation mixture to form misfolded αS aggregates; (C) subjecting the incubation mixture to excitation and detecting via indicator fluorescence emission the misfolded αS aggregates; and (D) diagnosing the subject has having PD or MSA depending on the fluorescence emission intensity. In some aspects, the incubation cycles are conducted in the presence of a bead.